Regenacy Pharmaceuticals Is Developing A Noveldisease Modifying Approach To Treating Peripheral Neuropathies That Goes Beyond Pain And Symptom Management To Restore Peripheral Nerve Function Our Lead Compound Ricolinostatacy 1215Is An Oralselective Inhibitor Of The Microtubule Modifying Enzyme Hdac6 With First In Class Potentialcurrently Positioned To Enter Phase 2 Clinical Trialsour Investigation Of Ricolinostat For Diabeticchemotherapy Induced And Inherited Peripheral Neuropathies Is Based On Compelling Proof Of Concept Preclinical Studies Demonstrating Restoration Of Normal Nerve Functionwe Were Founded In December 2016 Following The Acquisition Of Acetylon Pharmaceuticals By Celgeneregenacy Received Exclusive Rights To Ricolinostata Clinical Stageorally Bioavailablehdac6 Selective Inhibitorfor A Range Of Non Cancer Disease Indicationswe Also Have A Unique And Proprietary Portfolio Of Selective Hdac1 2 Inhibitors With Potential For Treating Cancerhemoglobinopathiesand Cognitive Dysfunction
